Carisma Therapeutics Inc. (CARM) scores 48 out of 100 on boothcheck's 11-model valuation framework. Verdict: Avoid The estimated fair value is 3.73, representing a 96% premium to fair value. Quantitative score: 39/100. Qualitative score: 9/100.
Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.